Literature DB >> 8819370

Analysis of interobserver and intraobserver variability in CT tumor measurements.

K D Hopper1, C J Kasales, M A Van Slyke, T A Schwartz, T R TenHave, J A Jozefiak.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the variability between radiologists interpreting thoracic and abdominal/pelvic CT scans in selecting specific sites of metastatic tumor for measurement (indicator lesions) and to assess interobserver and intraobserver variability in tumor measurement.
MATERIALS AND METHODS: Three separate experienced radiologists were asked to review 24 combined thoracic and abdominal CT scans in patients with metastatic tumor. Each radiologist was asked to identify the indicator lesions representative of each patient's tumor bulk. In the second phase of the study, 105 specific foci on 26 combined thoracic and abdominal CT studies (including the original 24) were reviewed twice by the same three radiologists. Up to eight foci were randomly identified per patient, and each observer was asked to determine the slice with the maximum diameter for each tumor focus and to measure it in three dimensions (maximum diameter, its perpendicular, and length).
RESULTS: A total of 132 tumor sites were present on the CT studies in phase I, all of which were chosen by at least one observer as an indicator lesion. Of the 116 of these that were separate and nonoverlapped, 57 (49%) were measured by only one observer, whereas 32 (28%) and 27 (23%) were measured by two or all three observers, respectively. Observers were more inclined to pick round or defined/well-defined lesions rather than irregular, oval, or poorly defined ones, although this tendency was not statistically significant. The second phase of the study showed considerable interobserver variability (15%) in CT tumor measurement, which was worse for poorly defined and irregular lesions. Intraobserver variability in measuring individual foci was less (6%).
CONCLUSION: Radiologists interpreting thoracic and/or abdominal/pelvic CT scans for metastatic cancer should measure and report a significant number of each patient's tumor sites, especially larger ones in different anatomic areas. When interpreting a follow-up CT scan of a patient with metastatic cancer, the interpreting radiologist should remeasure the indicator lesions on the previous and on the follow-up CT scans, especially when the results will change the patient's treatment response category.

Entities:  

Mesh:

Year:  1996        PMID: 8819370     DOI: 10.2214/ajr.167.4.8819370

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  47 in total

Review 1.  Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  Sarah J Vinnicombe; Rodney H Reznek
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-23       Impact factor: 9.236

Review 2.  Assessment of response to therapy using conventional imaging.

Authors:  Sheila C Rankin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-27       Impact factor: 9.236

3.  Reproducibility of linear tumor measurements using PACS: comparison of caliper method with edge-tracing method.

Authors:  Wayne L Monsky; Vassilios Raptopoulos; Mary T Keogan; David Doty; Ihab Kamel; Chun Sam Yam; Bernard J Ransil
Journal:  Eur Radiol       Date:  2003-12-05       Impact factor: 5.315

Review 4.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Authors:  Benjamin M Ellingson; Martin Bendszus; Jerrold Boxerman; Daniel Barboriak; Bradley J Erickson; Marion Smits; Sarah J Nelson; Elizabeth Gerstner; Brian Alexander; Gregory Goldmacher; Wolfgang Wick; Michael Vogelbaum; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Whitney B Pope; Dewen Yang; Caroline Chung; Michael V Knopp; Soonme Cha; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2015-08-05       Impact factor: 12.300

5.  Interobserver variability in the detection of mediastinal and hilar lymph nodes on CT in children with suspected pulmonary tuberculosis.

Authors:  Savvas Andronikou; Barbara Brauer; Jackie Galpin; Steven Brachmeyer; Susan Lucas; Elaine Joseph; George Dutoit; George Swingler
Journal:  Pediatr Radiol       Date:  2005-01-05

6.  The Lung Image Database Consortium (LIDC) data collection process for nodule detection and annotation.

Authors:  Michael F McNitt-Gray; Samuel G Armato; Charles R Meyer; Anthony P Reeves; Geoffrey McLennan; Richie C Pais; John Freymann; Matthew S Brown; Roger M Engelmann; Peyton H Bland; Gary E Laderach; Chris Piker; Junfeng Guo; Zaid Towfic; David P-Y Qing; David F Yankelevitz; Denise R Aberle; Edwin J R van Beek; Heber MacMahon; Ella A Kazerooni; Barbara Y Croft; Laurence P Clarke
Journal:  Acad Radiol       Date:  2007-12       Impact factor: 3.173

7.  Computer input devices: neutral party or source of significant error in manual lesion segmentation?

Authors:  James Y Chen; F Jacob Seagull; Paul Nagy; Paras Lakhani; Elias R Melhem; Eliot L Siegel; Nabile M Safdar
Journal:  J Digit Imaging       Date:  2011-02       Impact factor: 4.056

Review 8.  CAD (computed-aided detection) and CADx (computer aided diagnosis) systems in identifying and characterising lung nodules on chest CT: overview of research, developments and new prospects.

Authors:  F Fraioli; G Serra; R Passariello
Journal:  Radiol Med       Date:  2010-01-15       Impact factor: 3.469

9.  Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer.

Authors:  Binsheng Zhao; Leonard P James; Chaya S Moskowitz; Pingzhen Guo; Michelle S Ginsberg; Robert A Lefkowitz; Yilin Qin; Gregory J Riely; Mark G Kris; Lawrence H Schwartz
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

Review 10.  [Oncological imaging for therapy response assessment].

Authors:  J Stattaus
Journal:  Radiologe       Date:  2014-01       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.